Grail announced a private placement expected to raise approximately $325 million to support commercial activities, reimbursement efforts and working capital for its Galleri multi‑cancer early detection test. The financing includes participation from institutional investors and follows prior strategic investments and a separate Samsung commitment. Grail said proceeds plus existing cash will fund operations into 2030. Shares jumped over 15% on the financing announcement, signaling investor appetite for companies scaling novel diagnostics despite ongoing reimbursement and clinical‑utility debates. The raise underscores sustained capital flows into early‑detection platforms and will shape Grail’s market access push in multiple screening markets worldwide.